Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Nature Communications Année : 2024

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

C Grandclément
T Monney
T Matthes
Z Kaya
  • Fonction : Auteur
C M Edwards
J R Edwards
M R Dyson
Eugene Alexander Zhukovsky
  • Fonction : Auteur
M Perro
S Sammicheli

Résumé

Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bispecific antibody designed to re-establish synthetic immunity in CD38+ hematological malignancies. ISB 1442 consists of two anti-CD38 arms targeting two distinct epitopes that preferentially drive binding to tumor cells and enable avidity-induced blocking of proximal CD47 receptors on the same cell while preventing on-target off-tumor binding on healthy cells. The Fc portion of ISB 1442 is engineered to enhance complement dependent cytotoxicity, antibody dependent cell cytotoxicity and antibody dependent cell phagocytosis. ISB 1442 thus represents a CD47-BsAb combining biparatopic targeting of a tumor associated antigen with engineered enhancement of antibody effector function to overcome potential resistance mechanisms that hamper treatment of myeloma with monospecific anti-CD38 antibodies. ISB 1442 is currently in a Phase I clinical trial in relapsed refractory multiple myeloma.
Fichier principal
Vignette du fichier
s41467-024-46310-y.pdf (2.08 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : ETALAB - Licence Ouverte

Dates et versions

hal-04496386 , version 1 (08-03-2024)

Identifiants

Citer

C Grandclément, C Estoppey, E Dheilly, M Panagopoulou, T Monney, et al.. Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma. Nature Communications, 2024, 15, pp.2054. ⟨10.1038/s41467-024-46310-y⟩. ⟨hal-04496386⟩
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More